Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01933763 · ClinicalTrials.gov registry record · Phase 1
An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT01933763 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 56 participants.
The verdict
NCT01933763, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
Study to assess the safety and tolerability of ascending single-doses of REGN1193 in healthy volunteers.
Interventions
- OTHER Placebo
- DRUG REGN1193
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01933763
The ClinicalTrials.gov registry entry for NCT01933763 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01933763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01933763 about?
NCT01933763 is a clinical study titled "An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193". Study to assess the safety and tolerability of ascending single-doses of REGN1193 in healthy volunteers.
What is the current status of trial NCT01933763?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2013-08. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01933763?
The interventions under investigation include: Placebo (OTHER), REGN1193 (DRUG).
Who is sponsoring clinical trial NCT01933763?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.